Premium
Issues with the surgical treatment of antiresorptive agent‐related osteonecrosis of the jaws
Author(s) -
Kagami H,
Inoue M,
Kobayashi A,
Taguchi A,
Li X,
Yoshizawa M
Publication year - 2018
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12783
Subject(s) - denosumab , medicine , osteonecrosis of the jaw , surgery , disease , complication , bisphosphonate , osteoporosis
Antiresorptive agent‐related osteonecrosis of the jaw is a rare but significant complication in patients using antiresorptive agents such as bisphosphonates and denosumab. Although the disease is well recognized, and many studies have been performed on the management of this condition, the treatment of severe osteonecrosis is still a challenge. Most recent studies have shown an advantage of surgical treatment over conservative treatment for stage 2/3 patients, but there is no consensus on the appropriate surgical procedures for antiresorptive agent‐related osteonecrosis of the jaw. Furthermore, patients with severe systemic conditions may not be appropriate for extensive surgical treatment, and the treatment protocol for such patients has not been established. In this review, issues regarding the current surgical treatment for antiresorptive agent‐related osteonecrosis of the jaws are discussed, with an emphasis on the clinical aspects.